Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05NQX
|
||||
| Drug Name |
PD-152255
|
||||
| Synonyms |
164917-23-1; PD-152255
|
||||
| Indication | Unspecified | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Modulator | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Dopaminergic synapse | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.